Patents Assigned to Mt. Sinai School of Medicine of the City University of New York
  • Patent number: 5807999
    Abstract: The present invention relates to: 1) A monoclonal antibody (mAb) that binds selectively to phosphorylated histone H1 and not to nonphosphorylated histone H1 and its use. In one embodiment, the mAb of the present invention binds selectively to histone H1 phosphorylated at the 12D11 epitope as defined herein, and 2) A cell producing a monoclonal antibody which binds selectively to phosphorylated histone H1 and has been shown to distinguish between histone H1 phosphorylated at the 12D11 epitope and histone H1 nonphosphorylated at this epitope.
    Type: Grant
    Filed: February 1, 1993
    Date of Patent: September 15, 1998
    Assignee: Mt. Sinai School of Medicine of the City University of New York
    Inventor: D. Stave Kohtz
  • Patent number: 5545551
    Abstract: The present invention relates to the PUR protein, nucleotide sequences and expression vectors encoding PUR, and to methods for inhibiting PUR activity. Inhibitors of PUR activity may be used to treat hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: February 2, 1993
    Date of Patent: August 13, 1996
    Assignee: Mt. Sinai School of Medicine of the City University of New York
    Inventors: Edward M. Johnson, Andrew D. Bergmann
  • Patent number: 4959323
    Abstract: In accordance with the present invention, recombinant plasmids are described which, when inserted into microbial hosts, direct the synthesis of proteins in which preS polypeptides found on the surface of human hepatitis B virus are fused to the enzyme .beta.-galactosidase. The recombinant plasmids are produced by inserting DNA sequences encoding the preS polypeptides into the lacZ gene, which codes for E. coli .beta.-galactosidase, carried by the plasmids. Large amounts of the preS-.beta.-galactosidase fusion proteins can be isolated from microbial cultures carrying the recombinant plasmids. Antigenic determinants of fusion protein so produced are recognized by antibodies to the preS determinants of native hepatitis B virus. The .beta.-galactosidase activity of such fusion protein is detected by a suitable chromogenic or fluorogenic substrate. PreS-.beta.
    Type: Grant
    Filed: November 4, 1985
    Date of Patent: September 25, 1990
    Assignee: Mt. Sinai School of Medicine of the City University of New York
    Inventors: George Acs, Judith K. Christman, Peter Price, Wolf Offensperger, Silke Wahl
  • Patent number: 4328183
    Abstract: A solid-phase blood typing procedure is described based upon either aggluation or immune lysis. In this invention, a monolayer of cells is irreversibly bound to a solid matrix, and thereafter a serum containing antibodies is brought into contact with the bound cell layer. Immunoadsorption of antibodies by the bound cells occurs where the antigens of the cell membranes and the antibodies in the serum are complementary to each other. This antibody-sensitized monolayer of blood cells can either bind a second layer of blood cells carrying complementary antigen (solid-phase agglutination) or undergo lysis in the presence of serum lytic complement (solid-phase immune lysis). Carrying out these reactions with a monolayer of blood cells bound to a solid matrix allows quantitative evaluation of results by such standard instrumentable procedures as densitometric scanning, radioisotope counting, etc.
    Type: Grant
    Filed: July 18, 1980
    Date of Patent: May 4, 1982
    Assignee: Mt. Sinai School of Medicine of the City University of New York
    Inventors: Richard E. Rosenfield, Shaul Kochwa
  • Patent number: 4275053
    Abstract: A solid-phase blood typing procedure is described based upon either aggluation or immune lysis. In this invention, a monolayer of cells is irreversibly bound to a solid matrix, and thereafter a serum containing antibodies is brought into contact with the bound cell layer. Immuno-adsorption of antibodies by the bound cells occurs where the antigens of the cell membranes and the antibodies in the serum are complementary to each other. This antibody-sensitized monolayer of blood cells can either bind a second layer of blood cells carrying complementary antigen (solid-phase agglutination) or undergo lysis in the presence of serum lytic complement (solid-phase immune lysis). Carrying out these reactions with a monolayer of blood cells bound to a solid matrix allows quantitative evaluation of results by such standard instrumentable procedures as densitometric scanning, radioisotope counting, etc.
    Type: Grant
    Filed: June 14, 1978
    Date of Patent: June 23, 1981
    Assignee: Mt. Sinai School of Medicine of the City University of New York
    Inventors: Richard E. Rosenfield, Shaul Kochwa
  • Patent number: 4125626
    Abstract: The synthesis of L-.gamma.-glutamyl-DOPA (L-.gamma.-glutamyl-L-3,4-dihydroxy-phenylalanine) and its use selectively to increase renal blood flow in mammals.
    Type: Grant
    Filed: January 17, 1977
    Date of Patent: November 14, 1978
    Assignee: Mt. Sinai School of Medicine of the City University of New York
    Inventors: Marian Orlowski, Sherwin Wilk